SMMT - CIK 0001599298
Summit Therapeutics Inc. (SMMT) reported net income of -$1.08B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$1.08B | -387.8% |
| FY 2024 | -$221.31M | +64.0% |
| FY 2023 | -$614.93M | -680.5% |
| FY 2022 | -$78.78M | +11.1% |
| FY 2021 | -$88.60M | -68.1% |
| FY 2020 | -$52.70M | -80.9% |
| FY 2019 | -$29.13M | -368.0% |
| FY 2019 | $10.87M | +141.2% |
| FY 2018 |
Summit Therapeutics Inc. (SMMT) reported net income of -$1.08B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, Summit Therapeutics Inc.'s net income declined from -$26.35M to -$1.08B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$26.35M |
| - |